On November 7th 2017, Synbio Technologies is excited to be publicly listed on the NEEQ and we are eager to observe the benefits this listing brings. With this public listing, Synbio Technologies has become the first DNA manufacturing company to be listed on the NEEQ. We believe that this will be a unique opportunity for investors to observe the strong potential for growth the synthetic biology industry is capable of.
The synthetic biology industry itself is rapidly expanding with novel and groundbreaking achievements in technology by companies all over the world. Synbio Technologies is a cutting-edge DNA technology company that offers high-quality genetic products to customers all over the world. Founded in 2013, by Dr. Ping Yang. Synbio Technologies has evolved into one of the premier global gene synthesis and synthetic biology companies. In addition to being the first DNA manufacturing company listed on the NEEQ, Synbio Technologies has cultivated a large client base both in the US and abroad who are very excited for this opportunity, and will use this is a stepping stone to offer our customers high-quality synthetic biology services.
At Synbio Technologies, we are constantly looking to the future, and striving to contribute to the improving the synthetic biology industry. In doing so, we are constantly updating and improving our underlying methods of gene synthesis and synthetic biology services. This is seen in development of our Syno®1.0-3.0 Synthesis platform and its applications in other synthetic biology services. The field of synthetic biology is focused on the retooling and repurposing of innate biological mechanisms. For this reason, there is an endless supply of blueprints to work with and alter. This underlying principle allows companies like Synbio Technologies to continue to learn, grow, and innovate.
In the near future, we are working hard to increase our brand recognition and supply as many high-quality products to customers across the country. We believe that our listing on the NEEQ will supply us with much needed resources to continue to learn, grow, and innovate within the synthetic biology industry.
About Synbio Technologies
Synbio Technologies’ Syno®1.0-3.0 Platforms has enabled us to deliver millions of base pairs a year, while consistently offering 100% sequence accuracy for every base pair. The Syno® Synthesis Platform is a complete synthesis platform, capable of generating short oligos (Syno®1.0), gene constructs (Syno®2.0), and high throughput synthesis (Syno®3.0). This evolution is due to our novel approach toward gene synthesis and synthetic biology through our Genotype-Phenotype-Synotype (GPS) Platform. The GPS Platform combines three aspects of synthetic biology including design(genotype), manufacturing(synotype), and application(phenotype). Using the Syno®Synthesis Platform, Synbio Technologies offers our customers a wide variety of synthetic biology services.
The National Equities Exchange and Quotations (NEEQ) is a Chinese over-the-counter(OTC) system for trading shares of publicly listed companies. Founded in 2012, the NEEQ gives investors the ability to trade shares within the publicly listed company, while driving growth and development within the company itself. Currently, there are over 10,000 companies listed on the NEEQ, all of which offer different goods and services to their customers. A unique aspect about the NEEQ, being an OTC system, is that it offers the ability to trade commodities, financial instruments (stocks), and derivatives of such stocks.